HOME >> BIOLOGY >> NEWS
Multiple Chemical Sensitivity: A 1999 consensus

The Archives of Environmental Health announces publication of the first consensus definition of the controversial syndrome known as multiple chemical sensitivity (MCS). The 1999 Consensus on MCS, signed by 34 medical researchers and clinicians from the United States and Canada, appears in the May/June 1999 issue (volume 54, number 3). It defines MCS according to six criteria, the first five of which were identified in a survey of 89 clinicians representing a diverse range of medical specialties and opinions that the Archives published in 1993 (see Nethercott JR, Davidoff LL, Curbow B and Abbey H. 1993. Multiple chemical sensitivities syndrome: toward a working case definition. Arch Environ Health 48: 1926.) 1999 Consensus Criteria for Multiple Chemical Sensitivity

  1. The symptoms are reproducible with repeated [chemical] exposure.

  2. The condition is chronic.

  3. Low levels of exposure [lower than previously or commonly tolerated] result in manifestations of the syndrome.

  4. The symptoms improve or resolve when the incitants are removed.

  5. Responses occur to multiple chemically unrelated substances.

  6. Symptoms involve multiple organ systems.

The prior lack of any consensus definition has been a significant obstacle to the diagnosis of MCS in clinical practice. This definition is published with the hope that it may standardize the diagnosis of MCS in both clinical and research settings. According to epidemiological surveys conducted by the New Mexico Department of Health and California Department of Health Services, one sixth of randomly selected adults are adversely affected by chemical sensitivity to some degree, while 2% (in NM) to 8% in CA) say they have already been diagnosed with MCS by a medical professional. Dr. Kaye Kilburn, editor of the Archives of Environmental Health and one of the authors of the consensus, hailed the new MCS definition as a practical and orderly step that was overdue. Altho
'"/>

Contact: Ms. Pat McCready
aeh@heldref.org
301-384-0598
Heldref Publications
1-Jul-1999


Page: 1 2

Related biology news :

1. A new discovery by scientists at the MNI may provide insights into Multiple Sclerosis
2. Multiple lifestyle changes effectively lower blood pressure
3. Multiple factors affect flight power curves among species
4. Multiple births - their risks and how to prevent them
5. Multiple studies show that psyllium lowers cholesterol
6. Researcher Awarded Patent For System To Fight Multiple Diseases
7. Scientists Find Multiple New Uses For Worn-Out Tires
8. Relapses Prevented In Mouse Model Of Multiple Sclerosis: Research Aimed At Treating Relapses In Human MS
9. Protein Implicated In Multiple Sclerosis
10. Discovery By Fertility Specialist Offers Promise Of Reducing Multiple BirthsTied To Fertility Treatment
11. Common Cold Caused By Multiple Viruses

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Multiple Chemical Sensitivity consensus

(Date:6/16/2015)... , June 16, 2015 /CNW Telbec/ - handyem ... centralized around the incorporation of handyem,s HPC-150 portable ... laboratory, the Mo-POD™. This unprecedented model of mobile ... Conference at the Pennsylvania ... June 15 th to 18 th ...
(Date:6/16/2015)... , June 16, 2015 Fingerprint Cards ... fingerprint sensors in the company,s portfolio from one of its ... planned to mainly take place during the third quarter 2015. ... Asia . Jörgen Lantto, CEO of ...   the   growing interest from smartphone OEMs in integrating ...
(Date:6/15/2015)... June 16, 2015 According to ... by Type (Rule-Based, Statistical, and Hybrid), Technologies (Recognition, IVR, ... 2020" published by MarketsandMarkets, The Natural Language Processing Market ... CAGR of 18.4% for the forecast period 2015-2020. ... 46 F igures spread   through 155 P ...
Breaking Biology News(10 mins):handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 2handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 3FPC Receives Order for Touch Fingerprint Sensors of 375 MSEK 2Natural Language Processing Market Worth $13.4 Billion by 2020 2Natural Language Processing Market Worth $13.4 Billion by 2020 3Natural Language Processing Market Worth $13.4 Billion by 2020 4Natural Language Processing Market Worth $13.4 Billion by 2020 5
(Date:7/2/2015)... ... July 02, 2015 , ... In’Tech ... surgical instruments in Orthopedics, announced today the acquisition of Turner Medical, Inc ... provider of surgical instruments to the Spine Industry. The acquisition of Turner Medical ...
(Date:7/1/2015)... , July 1, 2015   Decision ... frequently cited advantages of Otezla are its oral ... profile, as reported by surveyed rheumatologists. Otezla was ... for the treatment of active psoriatic arthritis in ... current standard of care includes conventional oral treatments ...
(Date:7/1/2015)... ALTO, Calif. , July 1, 2015 /PRNewswire/ ... focused on the development of groundbreaking drugs to ... (ALS), announced today that Robert G. Miller ... Center at Sutter Health,s California Pacific Medical Center ... The ALS Association for $1.5 million to help ...
(Date:7/1/2015)... ... July 01, 2015 , ... A newly launched business plan ... lower the barriers to innovation in life sciences R&D. The Pistoia Alliance President’s Startup ... prizes of US$15,000 and a period of expert mentorship from a senior industry figure ...
Breaking Biology Technology:In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 2In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 3Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 2Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 2Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 4Pistoia Alliance Launches Startup Challenge 2Pistoia Alliance Launches Startup Challenge 3
Cached News: